Array BioPharma Updates Clinical Data On ARRY-614 For Myelodysplastic Syndromes

(RTTNews) - Array BioPharma Inc. (ARRY) announced updated clinical safety and efficacy data on ARRY-614 in patients with myelodysplastic syndromes or MDS.

Commenting on ARRY-614, the company said it is a potent inhibitor of p38/Tie2 with a mechanism of action distinct from drugs currently available to treat MDS. It is being studied in an ongoing dose-escalation trial in IPSS low/intermediate-1 risk MDS patients, representing a population of more than 100,000 patients in developed countries.

Of patients currently evaluable for efficacy, 21% achieved a Hematologic Improvement, as defined by International Working Group 2006 or IWG.